Drug news
European Commission approves Tradjenta (Eli Lilly/Boehringer) for treatment with insulin for patients with Type 2 Diabetes
Boehringer Ingelheim and Eli Lilly and Company announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes. The approval means linagliptin is now indicated for use in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.